Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: Influence of GH replacement therapy

Journal of Bone and Mineral Research

Volumn 21, Issue 4, 2006, Pages 520-528

  Mazziotti, Gherardo ^a   Bianchi, Antonio ^b   Bonadonna, Stefania ^a   Nuzzo, Monica ^a   Cimino, Vincenzo ^b   Fusco, Alessandra ^b   De Marinis, Laura ^b   Giustina, Andrea ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

Bone metabolism; Fracture; Growth hormone deficiency; Growth hormone replacement; IGF 1

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METABOLISM; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PREVALENCE; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SPINE MALFORMATION; SPINE RADIOGRAPHY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SPINE;

EID: 33645330427     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060112     Document Type: Article

References (56)

1. Ohlsson C, Bengtsson BA, Isaksson OGP, Andreassen TT, Slootweg MC 1998 Growth hormone and bone. Endocr Rev 19:55-79.
2. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797.
3. Corpas E, Harman SM, Blackman MR 1993 Human growth hormone and aging. Endocr Rev 14:20-39.
4. Raisz LG 1988 Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 318:818-828.
5. de Boer H, Blok GJ, Van der Veen EA 1995 Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16:63-86.
6. Carroll PV, Christ ER and the members of Growth Hormone Research Society Scientific Committee: Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorner M 1998 Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. J Clin Endocrinol Metab 83:382-395.
7. Lange M, Muller J, Svendsen OL, Kastrup KW, Juul A, Feldt-Rasmussen U 2005 The impact of idiopathic childhood-onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD. Clin Endocrinol (Oxf) 62:18-23.
8. de Boer H, Blok GJ, van Lingen A, Teule GJ, Lips P, van der Veen EA 1994 Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 9:1319-1326.
9. Toogood AA, Adams JE, O'Neill PA, Shalet SM 1997 Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 82:1462-1466.
10. Murray RD, Columb B, Adams JE, Shalet SM 2004 Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 89:1124-1130.
11. Ott SM 1990 Attainment of peak bone mass. J Clin Endocrinol Metab 71:1082A-2C.
12. Doga M, Bonadonna S, Gola M, Mazziotti G, Nuzzo M, Giustina A 2005 GH deficiency in the adult and bone. J Endocrinol Invest 28(Suppl 8):18-23.
13. Vandeweghe M, Taelman P, Kaufman JA 1993 Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxf) 39:409-415.
14. Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J 1998 Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 48:561-568.
15. Davidson P, Milne R, Chase D, Cooper C 2004 Growth hormone replacement in adults and bone mineral density: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 60:92-98.
16. Johannsson G, Ohlsson C 1998 Growth hormone therapy and fracture risk in the growth hormone-deficient adult. Baillieres Clin Endocrinol Metab 12:233-250.
17. Wuster C 2000 Fracture rates in patients with growth hormone deficiency. Horm Res 54(Suppl 1):31-35.
18. Wuster C, Slenczka E, Ziegler R 1991 Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: Need for additional growth hormone substitution? Klin Wochenschr 69:769-773.
19. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA 1997 Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137:240-245.
20. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P, on behalf of the KIMS Study Group and the KIMS International Board 2001 The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 16:398-405.
21. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in the osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984-996.
22. Grigoryan M, Guermazi A, Roemer FW, Delmas PD, Genant HK 2003 Recognizing and reporting osteoporotic vertebral fractures. Eur Spine J 12(Suppl.2):104-112.
23. Lindsay R. Pack S, Li Z 2005 Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int 16:306-313.
24. European Prospective Osteoporosis Study (EPOS) Group 2003 Determinants of the size of incident vertebral deformities in European men and women in the sixth to ninth decades of age: The European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 18:1664-1673.
25. Growth Hormone Research Society 1998 Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 83:379-381.
26. World Health Organization 1994 Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. World Health Organization, Geneva, Switzerland.
27. Kanis JA. Delmas P, Burckhardt P, Cooper C, Torgerson D 1997 Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7:390-406.
28. Ueland T 2005 GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 152:327-332.
29. Manelli F, Carpinteri R, Bossoni S, Burattin A, Bonadonna S, Agabiti Rosei E, Giustina A 2002 Growth hormone in glucocorticoid-induced osteoporosis. Front Horm Res 30:174-183.
30. Giustina A, Bussi AR, Jacobello C, Wehrenberg WB 1995 Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 80:122-129.
31. Agnusdei D, Gentilella R 2005 GH and IGF-I as therapeutic agents for osteoporosis. J Endocrinol Invest 28(Suppl 8):32-36.
32. Tracy JK, Meyer WA, Grigoryan M, Fan B, Flores RH, Genant HK, Resnik C, Hochberg MC 2006 Racial differences in the prevalence of vertebral fractures in older men: The Baltimore Men's Osteoporosis Study. Osteoporos Int 17:99-104.
33. Pivonello R, Colao A, Di Somma C, Facciolli G, Klain M, Faggiano A, Salvatore M, Lombardi G 1998 Impairment of bone status in patients with central diabetes insipidus. J Clin Endocrinol Metab 83:2275-2280.
34. Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Masaryk P, Pols HAP, Poor G, Reid DM, Scheidt-Nave C, Weber K, Varlow J, Kanis JA, O'Neill TW, Silman AJ 1997 Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: The EVOS Study. J Bone Miner Res 12:1883-1894.
35. Schuit SCE, van der Klift M, Weel AEAM, de Laet CEDH, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JPTM, Pols HAP 2004 Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 34:195-202.
36. Cefalu CA 2004 Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 20:341-349.
37. Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P 2000 Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 15:1368-1375.
38. Parfitt AM 1992 Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 13(Suppl 2):41-44.
39. Evans BAJ, Warner JT, Elford C, Evans SL, Laib A, Bains RK, Gregory JW, Wells T 2003 Morphological determinants of femoral strength in growth hormone-deficient transgenic growth-retarded (Tgr) rats. J Bone Miner Res 18:1308-1316.
40. Lange M, Qvortrup K, Lander Svendsen O, Flyvbjerg A, Nowak J, Petersen MM, Olgaard K, Feldt-Rasmussen U 2004 Abnormal bone collagen morphology and decreased bone strength in growth hormone-deficient rats. Bone 35:178-185.
41. Canalis E, Bilezikian JP, Angeli A, Giustina A 2004 Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593-598.
42. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A 2005 Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women. J Bone Miner Res 20:1837-1844.
43. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809.
44. Bravenboer N, Holzmann P, de Boer H, Roos JC, van der Veen EA, Lips P 1997 The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. J Clin Endocrinol Metab 82:1818-1822.
45. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S 2001 The relationship of health-related quality of life to prevalent and incident vertebral fractures in postemenopausal women with osteoporosis: Results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611-2619.
46. O'Neill TW, Cockerill W, Matthis C, Raspe HH, Lunt M, Cooper C, Banzer D, Cannata JB, Naves M, Felsch B, Felsenberg D, Janott J, Johnell O, Kanis JA, Kragl G, Lopes Vaz A, Lyritis G, Masaryk P, Poor G, Reid DM, Reisinger W, Scheidt-Nave C, Stepan JJ, Todd CJ, Woolf AD, Reeve J, Silman AJ 2004 Back pain, disability, and radiographic vertebral fracture in European women: A prospective study. Osteoporos Int 15:760-765.
47. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E 2003 Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254-1260.
48. Bates AS, Van't Hoff W, Jones PJ, Clayton RN 1996 The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81:1169-1172.
49. Rosen T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288.
50. Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, Mullis PE 2003 Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab 88:3664-3667.
51. Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen J 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1:1221-1225.
52. Bengtsson BA, Johannsson G 1999 Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults. Lancet 353:1898-1899.
53. Bengtsson BA, Johannsson G, Shalet SM, Simpson H, Sonken PH 2000 Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab 85:933-942.
54. Brooke AM, Monson JP 2003 Do all adults with growth hormone deficiency require growth hormone treatment? Ann Med 35:419-424.
55. Leal Cerro A 2004 Long-term challenges in growth hormone treatment. Horm Res 62(Suppl 4):23-30.
56. Biermasz NR, Hamdy NAT, Janssen YJH, Roelfsema F 2001 Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: A randomized controlled trial. J Clin Endocrinol Metab 86:3079-3085.